Monitor the shareholder vote scheduled for the Company Stockholders Meeting and track regulatory approval progress, as these are key milestones for deal completion.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $25.25entry
- T+1 · 7mo ago −0.01%α +0.48% · $25.25
- T+5 · 7mo ago −0.04%α −0.44% · $25.24
- T+20 · 6mo ago +0.44%α −4.52% · $25.36
- T+60 · 4mo ago −1.07%α −5.85% · $24.98
Price Chart
How similar events traded
Executive Summary
XOMA Royalty Corporation has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) tied to ongoing litigation. The deal, unanimously approved by both boards, is expected to close in Q3 2026 pending shareholder and regulatory approval.
Key Financial Metrics
Key Facts
- Ligand will acquire XOMA Royalty for $39.00 per share in cash, representing a 14% premium to XOMA's 30-day volume-weighted average price.
- XOMA shareholders will also receive one non-transferable contingent value right (CVR) per share, entitling them to 75% of net proceeds from the Janssen litigation.
- The transaction is expected to close in Q3 2026, subject to shareholder approval and regulatory clearance.
- XOMA's board unanimously approved the deal and recommended it to shareholders.
- BVF Partners, holding ~47% of voting power, has agreed to support the transaction through a voting agreement.
- The deal includes a $40 million termination fee if XOMA accepts a superior offer.
Financial Impact
Total equity value of approximately $739 million based on 12,129,405 shares outstanding at $39.00 per share, plus contingent value rights.
Risk Factors
- Failure to obtain shareholder approval
- Regulatory hurdles delaying or blocking the transaction
- Adverse outcome in the Janssen litigation affecting CVR value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-179093 |
| Document: 0001193125-26-179093-index-headers.html | 0001193125-26-179093 |
| Document: 0001193125-26-179093-index.html | 0001193125-26-179093 |
| Document: 0001193125-26-179093.txt | 0001193125-26-179093 |
Track record
6 reports on XOMAP
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.47% at T+20 after the May 26, 2026 report. 2 of 3 went positive at some point.
Filters
- Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $25.51 to $24.98 ▼ −2.07% −3.96% vs SPY
- May 26, 202624w ago 425 Bullish 7/10 Entry $25.36 to $25.48 ▲ +0.47% +2.42% vs SPY
- May 18, 202626w ago DEFA14A Neutral 4/10 Entry $25.38 to $25.40 ▲ +0.08% −1.50% vs SPY
- Apr 27, 202629w ago DEFA14A Bullish 8/10 Viewing Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Apr 27, 202629w ago 8-K Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Mar 30, 202633w ago DEFA14A Neutral 3/10 Entry $25.74 to $25.62 ▼ −0.47% −9.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers